- Stage
- In committee
- Started in
- House
- Sponsor
- 1
- Latest action
- Feb 12, 2026
What it does
The GAP Supply Act would amend the Federal Food, Drug, and Cosmetic Act to allow outsourcing facilities to continue compounding and distributing drugs for up to 180 calendar days after a drug enters shortage status, helping mitigate drug shortages. This change affects outsourcing facilities regulated under Section 503B by replacing the current requirement to stop production “at the time” a shortage is declared with a temporary “tail period” to maintain supply. The bill aims to enhance the resilience of the pharmaceutical supply chain by permitting continued production during shortages. It was introduced in the House and referred to the Committee on Energy and Commerce.
AI summary · The lawmakers haven’t published an official summary of this bill yet, so 52 wrote this one from the bill’s text.
Where it stands
Introduced (Done)
Committee (Current step)
Floor (Not started)
Law (Not started)
What moved
Who is involved
Sponsors
The lawmakers who put their names on it, lead sponsors first.
In the news
Reporting that may mention this subject. Possible matches are labeled.
Loading coverage…
Where it goes next
While a bill can still move, the questions are about people and money.